Epigenetics as a mechanism driving polygenic clinical drug resistance
about
Exploiting tumor epigenetics to improve oncolytic virotherapyEpigenetic therapy in gastrointestinal cancer: the right combinationA Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to TumorigenesisEmerging Role of miRNAs in the Drug Resistance of Gastric CancerEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaEnvironmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer PreventionEmerging therapeutic biomarkers in endometrial cancerPolo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancerTracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistanceMolecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP)A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsTreatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38α as a novel candidate for resistance."Persisters": survival at the cellular level.A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells.miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.The influence of cis-regulatory elements on DNA methylation fidelity.Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.Translational application of epigenetic alterations: ovarian cancer as a model.MicroRNA-mediated drug resistance in breast cancer.Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancerDown-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancerColorectal cancer: a model for epigenetic tumorigenesis.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.Broad targeting of resistance to apoptosis in cancer.MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10.Cytostatic drug treatment causes seeding of gene promoter methylation.A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemiaThe context and potential of epigenetics in oncologyCombined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivoPost-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance.Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Pharmaco(epi)genomics in ovarian cancer.
P2860
Q21131237-66C7AE4E-2E46-4E93-B821-7E498AEC4AF0Q26745709-533F18DB-CC49-485D-BDB8-55F241C9E6A7Q26746952-1B5F42FA-6C25-4173-9630-7EEE073F64D8Q26752006-E191360F-D458-4721-A75C-AD1C0FAD9B0BQ26783014-BC2DEEF5-908D-4D5C-8A20-53BE9899600FQ26784500-4E101DD9-79D7-4B4E-B49C-04A109354F8CQ26865904-4B42C36E-DDF4-49DC-A6AB-0ADC0944034AQ27030815-1C3D61FF-F3E7-4296-A129-A52DD691631EQ27335464-341918E0-8058-4C5D-A39E-2BBAFE0936B8Q28474284-A54A5AF6-81FF-4CB2-A1DF-610CF4FC45FDQ28741971-E64CC119-114A-451F-87DD-923885C52967Q29614275-162E95A9-F533-406A-8812-7A822B1233E3Q33416734-28243A04-4AEA-441C-A998-73DB31ED14F1Q33771409-0BA6DC99-6682-4710-9B58-E226DEA747B0Q33987400-5AB81FB2-1C56-4227-91F4-F3A82BDA9803Q34043011-906DF9E9-0748-45E0-B790-64CB1FF14DACQ34160439-9690BDA5-ADB7-4E3D-9391-125D1C8A3201Q34193554-BDFE7BC7-524F-4498-AEE9-66CE19A023BDQ35076298-77A5535F-4B17-40A4-A1E0-FE7EFD22A0C7Q35085782-08EE3A66-4AA7-40C0-B282-80BB783056E7Q35165126-27D499BB-5714-49C6-8CE3-94350CAF3ED9Q35214050-954BC6B2-045C-42A0-B26E-1A939B82A598Q35233239-D3202029-7584-4F5A-BF2C-82D727101662Q35238397-C9FDADC0-377A-4B5D-9894-157D25933BC2Q35377371-97E51C31-CE6D-412D-9FD5-BBE88E9B1CA7Q35739525-EA9B1739-5878-41A0-AD53-0E12355E517CQ35761237-79D0DE98-FB47-42AD-9160-7A3DA61BB770Q35782469-421773A0-513B-42F5-826D-4CC683887951Q36044905-04A0BB27-6642-4A45-8D98-1E3DDDA81E3BQ36213062-72236A94-8366-41A4-88E1-D993232EB370Q36483749-081C1E28-7675-4E01-B908-F0E8BE49E673Q36504323-ABF8CBF2-C9F7-42AE-B557-BA87E2EDCC0BQ36725766-75CA00C8-4042-4D37-9110-58F3FF9EBD30Q37109190-D175EA68-EEA5-4305-9824-F7843C355911Q37123413-E7869FC1-8AE8-4224-9AC7-434628939EB7Q37123516-5D846A45-0CD7-4EB0-B2C3-895398F4D867Q37139289-F7EEC2C3-701C-4D48-9343-3819ACEC853AQ37156891-9C3A960C-C52E-41BB-81EC-4D16095FC97BQ37232002-86D507C0-D660-4A1C-9088-F42C7AD0B03AQ37346198-A82D64E6-3CE2-4851-9239-F271AC5C9BDB
P2860
Epigenetics as a mechanism driving polygenic clinical drug resistance
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Epigenetics as a mechanism driving polygenic clinical drug resistance
@ast
Epigenetics as a mechanism driving polygenic clinical drug resistance
@en
Epigenetics as a mechanism driving polygenic clinical drug resistance
@nl
type
label
Epigenetics as a mechanism driving polygenic clinical drug resistance
@ast
Epigenetics as a mechanism driving polygenic clinical drug resistance
@en
Epigenetics as a mechanism driving polygenic clinical drug resistance
@nl
prefLabel
Epigenetics as a mechanism driving polygenic clinical drug resistance
@ast
Epigenetics as a mechanism driving polygenic clinical drug resistance
@en
Epigenetics as a mechanism driving polygenic clinical drug resistance
@nl
P2860
P3181
P356
P1476
Epigenetics as a mechanism driving polygenic clinical drug resistance
@en
P2093
J M Teodoridis
P2860
P2888
P304
P3181
P356
10.1038/SJ.BJC.6603024
P407
P577
2006-04-01T00:00:00Z
P5875
P6179
1036503911